D R Duerksen1, L M Lix2, H Johansson3,4, E V McCloskey3,5, N C Harvey6,7, J A Kanis3,4, W D Leslie2. 1. University of Manitoba, Winnipeg, Canada. dduerkse@sbgh.mb.ca. 2. University of Manitoba, Winnipeg, Canada. 3. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK. 4. Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia. 5. Centre for Integrated Research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK. 6. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. 7. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Abstract
Celiac disease is associated with an increased fracture risk but is not a direct input to the FRAX® calculation. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in the FRAX assessment, FRAX accurately predicts fracture risk. INTRODUCTION: The fracture risk assessment tool (FRAX®) uses clinical factors and bone mineral density (BMD) measurement to predict 10-year major osteoporotic (MOF) fracture probability. The study aim was to determine whether celiac disease affects MOF risk independent of FRAX score. METHODS: The Manitoba BMD Registry includes clinical data, BMD measurements, 10-year probability of MOF calculated for each individual using the Canadian FRAX tool and diagnosed celiac disease. Using linkage to population-based healthcare databases, we identified incident MOF diagnoses over the next 10 years for celiac disease and general population cohorts. RESULTS: Celiac disease (N = 693) was associated with increased fracture risk adjusted for FRAX score computed without secondary osteoporosis or BMD (adjusted hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.11-1.86). Celiac disease was no longer a significant risk factor for fracture when secondary osteoporosis or BMD were included in the FRAX calculation (p > 0.1). In subjects with celiac disease, each SD increase in FRAX score (calculated with and without secondary osteoporosis or BMD) was associated with higher risk of incident MOF (adjusted HR 1.66 to 1.80), similar to the general population (p-interaction > 0.2). Including celiac disease as secondary osteoporosis or including BMD in FRAX 10-year MOF probability calculations (10.1% and 8.6% respectively) approximated the observed cumulative 10-year MOF probability (10.8%, 95% CI 7.8-13.9%). CONCLUSIONS: Celiac disease is associated with an increased risk of major osteoporotic fractures. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in FRAX assessment, FRAX accurately predicts fracture risk.
Celiac disease is associated with an increased fracture risk but is not a direct input to the FRAX® calculation. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in the FRAX assessment, FRAX accurately predicts fracture risk. INTRODUCTION: The fracture risk assessment tool (FRAX®) uses clinical factors and bone mineral density (BMD) measurement to predict 10-year major osteoporotic (MOF) fracture probability. The study aim was to determine whether celiac disease affects MOF risk independent of FRAX score. METHODS: The Manitoba BMD Registry includes clinical data, BMD measurements, 10-year probability of MOF calculated for each individual using the Canadian FRAX tool and diagnosed celiac disease. Using linkage to population-based healthcare databases, we identified incident MOF diagnoses over the next 10 years for celiac disease and general population cohorts. RESULTS: Celiac disease (N = 693) was associated with increased fracture risk adjusted for FRAX score computed without secondary osteoporosis or BMD (adjusted hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.11-1.86). Celiac disease was no longer a significant risk factor for fracture when secondary osteoporosis or BMD were included in the FRAX calculation (p > 0.1). In subjects with celiac disease, each SD increase in FRAX score (calculated with and without secondary osteoporosis or BMD) was associated with higher risk of incident MOF (adjusted HR 1.66 to 1.80), similar to the general population (p-interaction > 0.2). Including celiac disease as secondary osteoporosis or including BMD in FRAX 10-year MOF probability calculations (10.1% and 8.6% respectively) approximated the observed cumulative 10-year MOF probability (10.8%, 95% CI 7.8-13.9%). CONCLUSIONS: Celiac disease is associated with an increased risk of major osteoporotic fractures. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in FRAX assessment, FRAX accurately predicts fracture risk.
Authors: William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis Journal: J Bone Miner Res Date: 2010-11 Impact factor: 6.741
Authors: Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray Journal: Am J Gastroenterol Date: 2013-04-23 Impact factor: 10.864
Authors: Lisa M Lix; Mahmoud Azimaee; Beliz Acan Osman; Patricia Caetano; Suzanne Morin; Colleen Metge; David Goltzman; Nancy Kreiger; Jerilynn Prior; William D Leslie Journal: BMC Public Health Date: 2012-05-18 Impact factor: 3.295
Authors: Jonas F Ludvigsson; Julio C Bai; Federico Biagi; Timothy R Card; Carolina Ciacci; Paul J Ciclitira; Peter H R Green; Marios Hadjivassiliou; Anne Holdoway; David A van Heel; Katri Kaukinen; Daniel A Leffler; Jonathan N Leonard; Knut E A Lundin; Norma McGough; Mike Davidson; Joseph A Murray; Gillian L Swift; Marjorie M Walker; Fabiana Zingone; David S Sanders Journal: Gut Date: 2014-06-10 Impact factor: 23.059